Converting p53 from a killer into a healer

Nature Medicine

Volumn 8, Issue 11, 2002, Pages 1196-1198

  Gudkov, Andrei V ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; SELENIUM DERIVATIVE; SELENOMETHIONINE;

DNA REPAIR; DRUG PROTEIN BINDING; GENE ACTIVATION; GENETIC STABILITY; PRIORITY JOURNAL; PROSTATE CANCER; SHORT SURVEY; TUMOR SUPPRESSOR GENE;

DNA REPAIR; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; PROSTATIC NEOPLASMS; SELENIUM COMPOUNDS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036852823     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1102-1196     Document Type: Short Survey

References (9)

1. Nelson, M.A., Porterfield, B.W., Jacobs, E.T. & Clark, L.C. Sernin. Urol. Oncol. 17, 91-96 (1999).
2. Seo, Y.R., Kelley, M., Smith, M.L. Selenomethionine regulation of p53 by a ref-1-dependent redox mechanism. Proc. Natl. Acad. Sci. USA; published online September 30, 2002, doi:qo.qo73/pnas.212319799.
3. Bernstein, C., Bernstein, H., Payne, C.M. & Garewal, H. DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: Fail-safe protection against carcinogenesis. Mutat. Res. 511, 145-78 (2002).
4. Prives, C. & Hall, P.A. The p53 pathway. J. Pathol. 187, 112-26 (1999).
5. Vousden, K.H. & Lu, X. Live or let die: The cell's response to p53. Nat. Rev. Cancer 2, 594-604 (2002).
6. Lane, D.P. & Lain, S. Therapeutic exploitation of the p53 pathway. Trends Mol. Med. 4, S38-42 (2002).
7. Komarov, P.G. et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285, 1733-1737 (1999).
8. Bykov, V.J. et al. Restoration of the tumor suppressor function to p53 by a low-molecular-weight compound. Nature Med. 3, 282-288 (2002).
9. Foster, B.A., Coffey, H.A., Morin, M.J. & Rastinejad, F. Pharmacological rescue of mutant p53 conformation and function. Science 286, 2507-2510 (1999).